Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by Dacoltson Mar 23, 2006 12:22pm
341 Views
Post# 10555661

Who might it be?

Who might it be?With the "extra" time on our hands I have been following the 3 biggest players in the stent business; Boston Scientific, Medtronics, and Johnson & Johnson. These three companies are currently battling each other for market share. In my opinion, Boston Scientific is out of the running with their current deal with Guidant. So in my mind that leaves Johnson & Johnson and Medtronics battling for our Revas. Just today Medtronics released news that stated that an "arbitration panel has found in favor of Medtronic, Inc in a case in which Johnson & Johnson/Cordis alleged that the Medtronic Driver™ stent and several other Medtronic stents infringed certain Cordis patents. The arbitration panel issued its non-appealable decision on February 20 and the award became final on March 22." I find this interesting. Could this be the delay we have experienced and could news be on its way? Any other thoughts out there?
Bullboard Posts